gila monster glp 1 discovery π¦ One of the world's most talked-about medicines owes a lot toβ¦ a venomous lizard. Researchers studying the saliva of the discovered a molecule similar to GLP-1. That helped Curious how a slow-moving lizard
Description
New trials suggest GLP-1 therapies may improve osteoarthritis pain and mobility in patients with obesity
With the participation of researchers from the Paul Langerhans Institute Dresden (PLID), partner at the German Center for Diabetes Research, a GLP-1 receptor agonist in the form of tablets could for the first time be compared with the most common second-line therapy of T2D, a DPP-IV inhibitor
PatchAid Difference
Tirzepatide was approved in 2022 as Mounjaro for diabetes, and in 2024 as Zepbound for obesity, with exclusivity running until May 2027
Demand for these drugs has increased rapidly in recent years, as indications have expanded, but they remain expensive
